Cancer Immunotherapy

  • Doreen E. SzollosiEmail author
  • Shannon R. M. Kinney
  • A. R. M. Ruhul Amin
  • Ngumbah Chumbow


Cancer is the second leading cause of death in the United States, accounting for approximately 23% of deaths from all causes. Cancer results from a multifactorial process characterized by uncontrolled cell growth as a result of inherited and de novo genetic mutations. Because their intrinsic regulation of gene expression has been altered from normal, cancer cells may resemble virus-infected cells in term of antigens produced. Thus, the immune system can typically identify, control, and eliminate precancerous cells the same way it would a virus-infected cell via recognition of MHC I. Abnormal cells that are able to avoid immune system recognition and removal will then have the opportunity to acquire more mutations, and continue to grow, ultimately developing into malignant tumors. There are various treatments for cancer that utilize immune targets, and depending on the type of cancer, they may suppress or even stimulate the immune system. Treatments for cancers of lymphocyte origin are generally aimed at suppressing their proliferation. Alternatively, immunotherapeutic treatments for certain tumors are aimed at stimulating the activation of T-cells that can help kill tumor cells. Other immunotherapeutic treatments utilize tumor-associated or specific antigens as targets of monoclonal antibodies in an effort to tag these cells for removal or alter their signaling processes. Because many cancer treatments often result in myelosuppression (anemia, neutropenia), treatment of chemotherapy-induced myelosuppression is also discussed.


Carcinoma Sarcoma Lymphoma Leukemia Myeloma Tumor-specific antigens Tumor-associated antigens MHC class I Cytotoxic T cells CAR-T VEGF Anemia Neutropenia Thrombocytopenia 

Suggested Reading

  1. Barkal AA, Weiskopf K, Kao KS, Gordon SR, Rosental B, Yiu YY, et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat Immunol. 2018;19:76–84.CrossRefGoogle Scholar
  2. Connell CM, Doherty GJ. Activating HER2 mutations as emerging targets in multiple solid cancers. ESMO Open. 2017;2(5):e000279.CrossRefGoogle Scholar
  3. Cooper MD, Peterson RD, Good RA. Delineation of the thymic and bursal lymphoid systems in the chicken. Nature. 1965;205:143–6.CrossRefGoogle Scholar
  4. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100(2):228–37.CrossRefGoogle Scholar
  5. D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91:4082–5.CrossRefGoogle Scholar
  6. DeVita VT, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68(21):8643–53.CrossRefGoogle Scholar
  7. Du FH, Mills EA, Mao-Draayer Y. Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. Auto Immun Highlights. 2017;8(1):12.CrossRefGoogle Scholar
  8. Ferreira JN, Correia LRBR, Oliveira RM, Watanabe SN, Possari JF, Lima AFC. Managing febrile neutropenia in adult cancer patients: an integrative review of the literature. Rev Bras Enferm. 2017;70(6):1301–8.CrossRefGoogle Scholar
  9. Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet. 2004;363:1802–11.CrossRefGoogle Scholar
  10. Gajria D, Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther. 2011;11(2):263–75.CrossRefGoogle Scholar
  11. Gao Z-W, Ke Dong K, Zhang H-Z. The roles of CD73 in cancer. Biomed Res Int. 2014;2014:460654.PubMedPubMedCentralGoogle Scholar
  12. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–99.CrossRefGoogle Scholar
  13. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70.CrossRefGoogle Scholar
  14. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.CrossRefGoogle Scholar
  15. Hassan MN, Waller EK. Treating chemotherapy-induced thrombocytopenia: is it time for oncologists to use thrombopoietin agonists? Oncology. 2015;29(4):295–6.PubMedGoogle Scholar
  16. Javier RT, Butel JS. The history of tumor virology. Cancer Res. 2008;68(19):7693–706.CrossRefGoogle Scholar
  17. King T, Jagger J, Wood J, Woodrow C, Snowden A, Haines S, Crosbie C, Houdyk K. Best practice for the administration of daratumumab in multiple myeloma: Australian myeloma nurse expert opinion. Asia Pac J Oncol Nurs. 2018;5(3):270–84.CrossRefGoogle Scholar
  18. Kourlaba G, Dimopoulos MA, Pectasides D, Skarlos DV, Gogas H, Pentheroudakis G, et al. Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer. Support Care Cancer. 2015;23(7):2045–51.CrossRefGoogle Scholar
  19. Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology. 2015;29(4):282–94.PubMedGoogle Scholar
  20. Leibbrandt A, Penninger JM. Novel functions of RANK(L) signaling in the immune system. Adv Exp Med Biol. 2010;658:77–94.CrossRefGoogle Scholar
  21. Li S, Pal R, Monaghan SA, Schafer P, Ouyang H, Mapara M, Galson DL, Lentzsch S. IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM. Blood. 2011;117:5157–65.CrossRefGoogle Scholar
  22. Lian Y, Meng L, Ding P, Sang M. Epigenetic regulation of MAGE family in human cancer progression-DNA methylation, histone modification, and non-coding RNAs. Clin Epigenetics. 2018;10:115.CrossRefGoogle Scholar
  23. Magen H, Muchtar E. Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment. Ther Adv Hematol. 2016;7(4):187–95.CrossRefGoogle Scholar
  24. Miller JF. Immunological function of the thymus. Lancet. 1961;2(7205):748–9.CrossRefGoogle Scholar
  25. Millrine D, Kishimoto T. A brighter side to thalidomide: its potential use in immunological disorders. Trends Mol Med. 2017;23:348–61.CrossRefGoogle Scholar
  26. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002a;99:4525–30.CrossRefGoogle Scholar
  27. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002b;99:4079–86.CrossRefGoogle Scholar
  28. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DV, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–44.CrossRefGoogle Scholar
  29. Nutt SL, Kee BL. The transcriptional regulation of B cell lineage commitment. Immunity. 2007;26(6):715–25.CrossRefGoogle Scholar
  30. Parcesepe P, Giordano G, Laudanna C, Febbraro A, Massimo Pancione M. Cancer-associated immune resistance and evasion of immune surveillance in colorectal cancer. Gastroenterol Res Pract. 2016;2016:6261721.CrossRefGoogle Scholar
  31. Ronson A, Tvito A, Rowe JM. Treatment of relapsed/refractory acute lymphoblastic leukemia in adults. Curr Oncol Rep. 2016;18(6):39.CrossRefGoogle Scholar
  32. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278–87.CrossRefGoogle Scholar
  33. Sharma P. Kumar P,2 and Sharma R. Natural killer cells—their role in tumour immunosurveillance. J Clin Diagn Res. 2017;11(8):BE01–5.PubMedPubMedCentralGoogle Scholar
  34. Sheskin J. Thalidomide in the treatment of Lepra reactions. Clin Pharmacol Ther. 1965;6:303–6.CrossRefGoogle Scholar
  35. Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer. 2015;15(6):361–70.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Doreen E. Szollosi
    • 1
    Email author
  • Shannon R. M. Kinney
    • 3
  • A. R. M. Ruhul Amin
    • 4
  • Ngumbah Chumbow
    • 2
  1. 1.Department of Pharmaceutical Sciences, School of Pharmacy and Physician Assistant StudiesUniversity of Saint JosephHartfordUSA
  2. 2.School of Pharmacy and Physician Assistant StudiesUniversity of Saint JosephHartfordUSA
  3. 3.College of Pharmacy and Health SciencesWestern New England UniversitySpringfieldUSA
  4. 4.Marshall University School of PharmacyHuntingtonUSA

Personalised recommendations